Found: 18
Select item for more details and to access through your institution.
Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study.
- Published in:
- BJU International, 2022, v. 130, n. 6, p. 799, doi. 10.1111/bju.15769
- By:
- Publication type:
- Article
Change in prostate volume during extreme hypofractionation analysed with MRI.
- Published in:
- Radiation Oncology, 2014, v. 9, n. 1, p. 1, doi. 10.1186/1748-717X-9-22
- By:
- Publication type:
- Article
Change in prostate volume during extreme hypo-fractionation analysed with MRI.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden.
- Published in:
- Scandinavian Journal of Urology, 2023, v. 58, n. 1, p. 93, doi. 10.2340/sju.v58.9572
- By:
- Publication type:
- Article
The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease.
- Published in:
- Scandinavian Journal of Urology, 2022, v. 56, n. 4, p. 265, doi. 10.1080/21681805.2022.2094462
- By:
- Publication type:
- Article
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
- Published in:
- Scandinavian Journal of Urology, 2022, v. 56, n. 4, p. 278, doi. 10.1080/21681805.2022.2093396
- By:
- Publication type:
- Article
Improved PET/MRI attenuation correction in the pelvic region using a statistical decomposition method on T2-weighted images.
- Published in:
- EJNMMI Physics, 2020, v. 7, n. 1, p. N.PAG, doi. 10.1186/s40658-020-00336-5
- By:
- Publication type:
- Article
Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 4, p. 846, doi. 10.1002/1878-0261.13158
- By:
- Publication type:
- Article
Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.
- Published in:
- Acta Oncologica, 2023, v. 62, n. 12, p. 1698, doi. 10.1080/0284186X.2023.2254480
- By:
- Publication type:
- Article
Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study.
- Published in:
- Radiation Oncology, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13014-022-02197-x
- By:
- Publication type:
- Article
Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5195, doi. 10.3390/cancers14215195
- By:
- Publication type:
- Article
High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2424, doi. 10.3390/cancers13102424
- By:
- Publication type:
- Article
Deep learning-based classification and structure name standardization for organ at risk and target delineations in prostate cancer radiotherapy.
- Published in:
- Journal of Applied Clinical Medical Physics, 2021, v. 22, n. 12, p. 51, doi. 10.1002/acm2.13446
- By:
- Publication type:
- Article
Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
- Published in:
- International Journal of Cancer, 2024, v. 155, n. 4, p. 637, doi. 10.1002/ijc.34932
- By:
- Publication type:
- Article
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens.
- Published in:
- Prostate, 2020, v. 80, n. 2, p. 214, doi. 10.1002/pros.23935
- By:
- Publication type:
- Article
Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases.
- Published in:
- Prostate, 2019, v. 79, n. 14, p. 1683, doi. 10.1002/pros.23893
- By:
- Publication type:
- Article
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
- Published in:
- Prostate, 2018, v. 78, n. 1, p. 48, doi. 10.1002/pros.23443
- By:
- Publication type:
- Article